Description
Created On: 2020-07-15
Record Count: 10
Primary Industries
- Drugs
- Disease
- Therapeutic
- Weight Loss
- Cancer
- Diagnostic
- Drug Discovery
- Cannabis
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 245900
Licensed Patents:
U.S. provisional patent application USSN 60/965,135 entitled Therapeutic Compositions for Treatment of Inflammation of Ocular and Adnexal Tissues
PCT/US08/09776 filed on 15.08.2008 claiming priority to Provisional 60/965,135, filed on August 16 2007. Published on February 26, 2009 WO/2009/025763, entitled Therapeutic Compositions for Treatment of Inflammation of Ocular and Adnexal Tissues
Provisional 61/143,561 filed January 09. 2009 entitled Therapeutic Compositions For Treatment of Corneal Disorders
Licensed Product means any product the manufacture, use or sale of which would, but for the licenses granted in this Agreement, infringe a Valid Claim of a Licensed Patent.
An amendment to the license agreement dated 01/01/1990 is amended by deleting it in its entirety the above Licensed Patent Information and replacing it hereto:
Licensed Patents:
U.S. Patent Appln. No. 121685.510
U.S. Patent Appln. No. 13/183,231
IPSCIO Record ID: 239034
U.S. #1
(a) First US provisional filed January 22, 2001 (60/262,651).
(b) Second US provisional filed February 8, 2001 (60/267,196).
(c) Third US provisional filed July 19, 2001 (60/306,140)
(d) A regular US patent application (10/051,309) was filed on January 22, 2002, claiming priority to the above-mentioned three US provisional applications.
U.S. #2
(a) First US provisional filed February 8, 2001 (60/267,195)
(b) Second US provisional filed January 7, 2002 (60/344,824).
(c) A regular US patent application (10/067,996) was filed on February 8, 2002, claiming priority to the above-mentioned two US provisional applications.
(d) Possible Second US family to be filed; awaiting analysis from MPC.
U.S.#3
A first US provisional application (Memory 3 VI) was filed October 16, 2001 (60/329,314).
U.S. #4
(a) First US provisional filed November 15, 2001 (60/331,422)
(b) Second US provisional filed January 23, 2002 (60/349,985).
U.S. #5
(a) U.S. provisional application filed June 25, 1999 (60/141,196
(b) A regular U.S. Patent Application was filed June 23, 2000 (09/602,735), claiming priority to the above-mentioned provisional application.
Product means any and all products that include, in whole or as a component thereof, a Licensor Compound or a Collaboration Compound.
Patent Right means all rights under any patent or patent application in any country of the Territory, including any substitution, extension or supplementary protection certificate, reissue, reexamination, renewal, division, continuation or continuations-in-part thereof.
Licensor Patent Rights means all Patent Rights that Licensor owns, or otherwise has the right to grant the licenses herein, during the Agreement Term. Below lists all U.S. Licensor Patent Rights that Cover the Licensor Compounds as of the date hereof (Base Patents).
Licensor Compound means any PDE4 inhibitor for which Licensor either prior to the Effective Date or during the Agreement Term has rights, whether by reason of its own conception of such inhibitor, or under agreement with a Third Party.
Collaboration Compound means any PDE4 inhibitor that (i) either or both Parties or its Affiliates conceives in the conduct of the Research Collaboration, or (ii) the JLT otherwise agrees shall constitute a Collaboration Compound pursuant to the Research Workplan.
'Neurological Indication' means prophylaxis or treatment of Alzheimers' disease, prophylaxis or treatment of mild cognitive impairment ('MCI') or treatment of vascular dementia.
'Non-Memory Compound' means a PDE4 inhibitor, other than a Memory Compound or a Collaboration Compound, with respect to which the initial IND for the inhibitor is for a Neurological Indication or Psychiatric Indication.
'Psychiatric Indication' means depression, anxiety or mixed anxiety/depression.
MEM 1917 is a PDE4 inhibitor that we are developing for the treatment of depression.
IPSCIO Record ID: 294019
Licensed Patents means that certain U.S. Patent No. 5,310,562; and all corresponding foreign patent applications and patents throughout the Territory, including any and all divisions, re-issues, re-examinations, renewals, continuations and substitutes in whole or in part of such patents and patent applications in the Territory with respect to the anti-fibrotic uses of Pirfenidone; and all Patents defined. The Licensed Patents shall specifically exclude U.S. Patent No. 5,962,478 titled Tumor Necrosis Factor Alpha.
5,310,562 – Composition and method for reparation and prevention of fibrotic lesions
Patents means all of Licensors (a) anti-fibrotic, Pirfenidone patent applications heretofore or hereafter filed or having legal force in any country including without limitation divisionals, continuations, continuation-in-part and provisional applications; (b) issued, unexpired anti-fibrotic Pirfenidone patents in any country, including utility, model and design patents and certificates of invention; and (c) substitutions, extensions, reissues, renewals, and supplementary protection certificates with respect to any such issued patents. For clarity, such patent applications and patents shall include those owned, as well as those controlled with the right to grant licenses, by any of Licensors. The Patents shall not include patent applications and patents to the extent claiming uses of Pirfenidone other than for anti-fibrotic uses, nor uses of compounds for anti-fibrotic applications other than Pirfenidone.
Fibrosis, also known as Fibrotic scarring, is a pathological wound healing in which connective tissue replaces normal parenchymal tissue to the extent that goes unchecked, leading to considerable tissue remodelling and the formation of permanent scar tissue.
IPSCIO Record ID: 243496
Assignment; License-Back. Licensee hereby assigns, transfers, conveys and delivers to Licensor, and Licensor hereby accepts all and every right, title and interest of Licensee in and to the Licensee Patent Rights listed, together with all ancillary rights thereto, including the right to sue for damages by reason of past infringement of any such rights; and the Licensee Intellectual Property owned by Licensee that relates directly to such Licensee Patent Rights (collectively, the Assigned Technology).
Covered Product(s) means any product the Development, Manufacture, use or sale of which is covered by the Licensee Patent Rights or makes use of any Licensee Intellectual Property.
Patent Rights means any and all (a) issued patents and (b) pending patent applications, including all provisional applications, substitutions, divisionals, continuations, continuations-in-part, renewals, and all letters of patent granted with respect to any of the foregoing, (c) patents of addition, restorations, reissues, extensions, supplementary protection certificates, registration or confirmation patents, patents resulting from post-grant proceedings, re-examinations; (d) inventor’s certificates; and (e) other forms of government issued rights substantially similar to any of foregoing, in each any country in the Territory.
Licensee Intellectual Property means Know-How that is Controlled by Licensee or its Affiliates during the term of this Agreement and that is reasonably necessary or useful for or directly related to the Development, Manufacture or Commercialization of the Covered Products. The term Licensee Intellectual Property does not include (a) any Know-How, which is, as of the Effective Date or later becomes, generally available to the public, excluding Licensee Confidential Information or Know-How Controlled by Licensee or its Affiliates that is publicly disclosed by a Third Party without the consent of Licensee, and Know-How included in Licensee Patent Rights
Licensee Patent Rights means those Patent Rights that Cover Licensee Intellectual Property and are Controlled by Licensee or its Affiliates at any time during the term of this Agreement. Licensee Patent Rights as of the Effective Date are listed which shall be updated in writing from time to time, at least annually, during the term of this Agreement.
Title: Flagellin compositions
Jurisdiction: USA
Application Detials: 15/329,870, Filing Date: 07-29-2015, Priority Date: 07-30-2014
Patent Details: N/A
Status: Pending
Title: Flagellin compositions and uses including effective vaccination
Jurisdiction: USA
Application Details: 15/500,133, Filing Date: 07-30-2015, Priority Date: 07-30-2014
Patent Details: N/A
Status: Pending
IPSCIO Record ID: 252854
Licensed Technology shall mean and include but not limited to:
(i) the technologies, inventions and know-how associated with the VCU Invention Disclosures listed,
(ii) SRA (Sponsored Research Agreement) technology, inventor improvement(s), collaboration improvements and any non-inventor improvements(s) that Licensee elects to add to this agreement.
Licensed Patent Rights shall mean (a) those patent applications listed and patents issuing therefrom, any foreign equivalents thereof, and any and all United States (and foreign equivalents of) extensions, substitutions, continuations, confirmations, divisions, reissues, reexaminations, restorations, registrations and continuation-in-part applications that are entitled to the priority date of any such applications, with respect to any or all of the foregoing, in each case as of the effective date and thereafter that are filed or issued during the term of this Agreement, and enforcement rights; (b) those United States and foreign patent applications and patents disclosing, covering or claiming any Licensed Technology and, in each case, any and all United States (and foreign equivalents of) extensions, substitutions, continuations, confirmations, divisions, reissues, reexaminations, restorations, registrations and continuation-in-part applications that are entitled to the priority date of any such applications, with respect to any or all of the foregoing, that are filed or issued during the term of this Agreement, and enforcement rights.
Provisional Serial No. 60/621,537, filed October 25, 2004 – Nuclear Oxysterol, Potent Regulator Of Cholesterol Homeostasis, For Therapy Of Hypercholesterolemia, Hyperlipidemia, and Atherosclerosis
Non-Provisional Serial No. 11/739,330, filed April 26, 2007 – Nuclear Sulfated Oxysterol, Potent Regulator Of Cholesterol Homeostasis, For Therapy Of Hypercholesterolemia, Hyperlipidemia, and Atherosclerosis
Provisional Serial No. 61/154,063, filed February 20, 2009 – 5-Cholesten-3b , 25-diol 3-sulfate (25HC3S), an authentic PPARy agonist and LXR antagonist, or the therapy of inflammatory diseases
SRA Technology means Project Technology (defined in the SRA) and any technology, data, ideas, inventions, discoveries and improvements, and the intellectual property rights therein and thereto including Project Patent Rights (defined in the SRA) and enforcement rights, that are developed, generated, made, conceived or reduced to practice, in whole or in part, by inventor(s), alone or with others, directly or indirectly in the performance or as a result of the SRA Project (defined in the SRA).
IPSCIO Record ID: 223124
RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing specific genes, an ability that could become the basis for a whole new class of therapeutic products. The discovery of RNAi has been heralded by many as a major breakthrough, and the journal Science named RNAi the top scientific achievement of 2002 as well as one of the top ten scientific advances of 2003. Because many diseases are caused by the inappropriate activity of specific genes, the ability to silence such genes selectively through RNAi could provide a means to treat a wide range of human diseases.
Licensed Patents means the U.S. Patent Applications listed below and any divisions, continuations, reissues, reexamines, extensions and continuations-in-part applications thereof and any patents issuing thereto; and any and all foreign patents, foreign applications, extensions and supplemental protection certificates or patent applications corresponding thereto having the Principal Investigator as an inventor and claiming the same priority date as a parent application.
Licensor Patents
Serial No. Type Tite Date Filed Status
PCT/US01/08435 PCT Methods and Compositions for RNA Interference 3/16/01 Published
09/858,862 CIP Methods and Compositions for RNA Interference 5/16/01 Pending
09/866,551 CIP Methods and Compositions for RNA Interference 5/24/01 Pending
10/055,797 CIP Methods and Compositions for RNA Interference 1/22/02 Pending
Licensed Product means any product, including but not limited to any lyophilized liquid, sustained release or aerosolized formulation or other formulation, or process for which Licensee, or its Affiliate has received FDA Approval and/or Regulatory Approval, which is made through the use of Licensor Know-How or falls within the scope of a Valid Claim of a Licensed Patent.
IPSCIO Record ID: 271451
The Parties also agree hereby on the financial compensation for the assignment by Assignor to Assignee and/or its Affiliates of any rights on and to Future Results including any rights as a co-inventor of patentable inventions to be covered by Future Patent Applications.
The provisions of this Agreement shall only apply to Results generated by Assignor during the period ending on the earlier of (i) the term of this Agreement and (ii) the Employment Period.
No. 1. The French patent application n°FR1753775 filed on April, 28th 2017 and entitled “20-Hydroecdysone extract of pharmaceutical grade, its use and its preparationâ€.
No. 2. The French patent application n°FR1758071 filed on May, 31st 2017 and entitled “Use of 20-hydroxyecdysone and the derivatives thereof in the treatment of myopathiesâ€.
No. 3. The French patent application n°FR1851778 filed on February, 28th 2018 and entitled “Phytoecdysones for their use in the prevention of the loss of muscular strength during an immobilisation†.
No. 4. The French patent application n°FR 1902726, entitled “Phytoecdysones and their derivatives for their use in the treatment of neuromuscular diseases “.
No. 5. The French patent application n°FR 1902727, entitled “Phytoecdysones and their derivatives for their use in the treatment of alterations of the respiratory functionâ€.
As well as any and all (I) provisional and non-provisional applications, foreign patent application, patent cooperation treaty (PCT) applications, substitutions, continuations, continuations-in-part, divisions and renewals of the above describe patent applications, (ii) all patents granted thereon, and (iii) all reissues, re-examinations and extensions or restorations, including supplementary protection certificates or the equivalent thereof, granted thereon and corresponding priority rights.
Existing Patents means the patent applications filed by Licensee before July 13, 2015 as well as any and all (I) provisional and non-provisional applications, foreign patent application, patent cooperation treaty (PCT) applications, substitutions, continuations, continuations-in-part, divisions and renewals of such patent applications, (ii) all patents granted thereon, and (iii) all reissues, re-examinations and extensions or restorations, including supplementary protection certificates or the equivalent thereof, granted thereon and corresponding priority rights.
Future Patent Application means (I) any patent or patent application based on Current Results for which Assignor is designated as an inventor or co-inventor and/or (ii) a patent application filed on the basis of Future Results and for which Licensor is designated as an inventor or co-inventor, as well as any and all (x) provisional and non-provisional applications, foreign patent application, patent cooperation treaty (PCT) applications, substitutions, continuations, continuations-in-part, divisions and renewals of such patent applications described in (I) and (ii), (y) all patents granted thereon, and (z) all reissues, re-examinations and extensions or restorations, including supplementary protection certificates or the equivalent thereof, granted thereon and corresponding priority rights.
The myopathies are neuromuscular disorders in which the primary symptom is muscle weakness due to dysfunction of muscle fiber.
IPSCIO Record ID: 273408
US Patent Application SN 10/440,404, entitled, 'Method for Treating Obesity' and filed May 19, 2003. (Atising from Licensor Office of Science and Technology File #2081)
PCT Patent Application PCT/US03/15703, entitled, 'Method of Treating Obesity and filed May 19, 2003. (Arising from Licensor Office of Science and Technology File #2081) US Provisional Patent Application SN 60/535,799, entitled, 'Method of Reducing Weight Gain Risk Associated with Antidepressant Therapy' and filed January 13, 2004. (Arising from Licensor Office of Science and Technology File# 2308)
US Provisional Patent Application SN 60/535,800, entitled Method of Reducing Weight Gain Risk Associated with Antipsychotic Therapy' and filed January 13, 2004. (Arising from Licensor Office of Science and Technology File #2294)
Licensed Product shall mean any product or part thereof which: (a)
is covered in whole or in part by any valid claim contained in the Licensor Patent Rights in the country in which any such product or part thereof is made, used or sold; and/or (b) is manufactured by using a process or is employed to practice a process which is covered in whole or in part by a valid claim contained in the Licensor Patent Rights in the country in which any Licensor Licensed Process is used or in which such product or part thereof is used or sold; and/or c)
in its intended use, practices, incorporates, or otherwise utilizes, in whole, or in part, a valid claim contained in the Licensor Patent Rights in the country in which any such product or part thereof is made, used, or sold.
Licensed Process shall mean any process which is covered in whole or in part by a valid claim contained in the Licensor Patent Rights.
Licensed Service shall mean any service provided by Licensee (and/or sublicensees, as the case may be) to a third party which utilizes Licensor Licensed Products and/or Licensor Licensed Processes.
IPSCIO Record ID: 235007
Licensed Patents shall mean any and all rights arising out of or resulting from (i) the patents and patent application set forth in this Agreement, as well as any additional patents or patent applications related to any aspect of any Licensed Technology Improvements, Licensed Know-how, Licensed Products, and/or Licensed Technology (as herein defined) filed prior to or during the term of this Agreement and (ii) any letters patent granted in respect of all such applications, as well as, without limitation, any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, re-examinations, extensions, supplementary protection certificates, confirmations, registrations, revalidations and the like, of any and all such patents and patent applications and any international equivalents thereof.
Country Status Application # Filing Date Publication # Publication Date
United States
Published
14/649,951
05-Jun-2015
2015-0313868
05-Nov-2015
United States
Expired
61/738,782
18-Dec-2012
Licensed Technology shall mean the aggregate of the Licensed Inventions, the Licensed Know-how, the Licensed Products and the Licensed Patents and any other information and/or technology related to the Licensed Products and/or the design and/or the manufacturing of the Licensed Products.
Licensed Inventions shall mean the inventions claimed in the Licensed Patents.
The licensed intellectual property includes patent applications relating to the use of cannabinoid receptor modulators and terpenes in the acute treatment during exposure to organophosphorus nerve agents and/or organophosphorus insecticides.
IPSCIO Record ID: 273410
US Patent Application SN 10/440,404, entitled, 'Method for Treating Obesity' and filed May 19, 2003. (Atising from Licensor Office of Science and Technology File #2081)
PCT Patent Application PCT/US03/15703, entitled, 'Method of Treating Obesity and filed May 19, 2003. (Arising from Licensor Office of Science and Technology File #2081)
US Provisional Patent Application SN 60/535,799, entitled, 'Method of Reducing Weight Gain Risk Associated with Antidepressant Therapy' and filed January 13, 2004. (Arising from Licensor Office of Science and Technology File# 2308)
US Provisional Patent Application SN 60/535,800, entitled Method of Reducing Weight Gain Risk Associated with Antipsychotic Therapy' and filed January 13, 2004. (Arising from Licensor Office of Science and Technology File #2294)
Licensed Product shall mean any product or part thereof which:
(a)
is covered in whole or in part by any valid claim contained in the Licensor Patent Rights in the country in which any such product or part thereof is made, used or sold; and/or
(b)
is manufactured by using a process or is employed to practice a process which is covered in whole or in part by a valid claim contained in the Licensor Patent Rights in the country in which any Licensor Licensed Process is used or in which such product or part thereof is used or sold; and/or
c)
in its intended use, practices, incorporates, or otherwise utilizes, in whole, or in part, a valid claim contained in the Licensor Patent Rights in the country in which any such product or part thereof is made, used, or sold.
Licensed Process shall mean any process which is covered in whole or in part by a valid claim contained in the Licensor Patent Rights.
Licensed Service shall mean any service provided by Licensee (and/or sublicensees, as the case may be) to a third party which utilizes Licensor Licensed Products and/or Licensor Licensed Processes.